David Watson

发表

Effect of Darapladib onMajor Coronary Events After an Acute Coronary Syndrome The SOLID-TIMI 52 Randomized Clinical Trial

Dylan L. Steen, Marc P. Bonaca, E. Braunwald, 2014 .

Darapladib for preventing ischemic events in stable coronary heart disease.

P. Pais, Á. Avezum, A. Parkhomenko, 2014, The New England journal of medicine.

Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease.

C. Held, C. Cannon, H. White, 2010, American heart journal.

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Diane M. Miller, Natalia E. Shilkina, M. C. Cantero, 2018, Lancet.

Health Care Resource Use After Acute Stroke in the Glycine Antagonist in Neuroprotection (GAIN) Americas Trial

T. Rundek, S. Phillips, K. Johnston, 2004, Stroke.

Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease

C. Held, E. Lonn, H. White, 2016, European heart journal.

Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.

Dylan L. Steen, Marc P. Bonaca, E. Braunwald, 2014, JAMA.

Abstract 18856: Relationships Between ‘Mediterranean’ and ‘Western’ Dietary Patterns and Major Cardiovascular Events in Patients With Stable Coronary Heart Disease in the STABILITY Study

C. Held, E. Lonn, H. White, 2014 .

Abstract 19384: Favorable Association Between a Mediterranean Dietary Pattern and Cardiovascular Risk Factors in Patients with Stable Coronary Heart Disease in the STABILITY Study

C. Held, E. Lonn, E. Hagström, 2014 .